Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes
Annals of Internal Medicine · 2026
DOI: 10.7326/annals-25-04623 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Ming Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University General Hospital, Tianjin, China (M.L.). Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 36 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Bofanglutide is a novel glucagon-like peptide-1 receptor agonist under development for type 2 diabetes mellitus (T2DM) and overweight and obesity. OBJECTIVE: To evaluate the efficacy and safety of bofanglutide compared with semaglutide. DESIGN: Phase 2b, randomized, open-label, active-controlled trial. (ClinicalTrials.gov: NCT06256549). SETTING: Multicenter (37 sites in China). PARTICIPANTS: Adults with T2DM who were drug-naive or receiving stable oral antidiabetic drugs (glycated hemoglobin A1c [HbA1c], 7.0% to 11.0%). INTERVENTION: Participants were randomly assigned 1:1:1:1:1 to 1 of 5 treatment groups: bofanglutide titrated to targets of 12, 18, or 24 mg (biweekly [once every 2 weeks; Q2W]); bofanglutide titrated to 24 mg (once weekly [QW]); or semaglutide titrated to 1 mg QW. MEASUREMENTS: Change in HbA1c level from baseline to week 24 (primary end point), secondary efficacy end points, and safety. RESULTS: Overall, 272 participants were enrolled, with a mean age of 50.8 years, HbA1c level of 8.35%, and body mass index of 27.9 kg/m2. At week 24, HbA1c level change from baseline was -1.87% (95% CI, -2.11% to -1.63%), -2.28% (CI, -2.54% to -2.03%), and -1.94% (CI, -2.19% to -1.69%) for bofanglutide 12, 18, 24 mg Q2W, respectively; -2.32% (CI, -2.57% to -2.06%) for bofanglutide 24 mg QW; and -1.60% (CI, -1.85% to -1.35%) for 1 mg of semaglutide QW. Corresponding treatment differences versus semaglutide were -0.27% (CI, -0.61% to -0.08%), -0.68% (CI, -1.04% to -0.33%), -0.34% (CI, -0.70% to 0.02%), and -0.72% (CI, -1.08% to -0.36%), respectively. Gastrointestinal adverse events (GIAEs) (mostly grade 1 or 2 in severity) occurred in 81.8% to 87.3% and 51.9% of participants in the bofanglutide and semaglutide groups, respectively. Hypoglycemia occurred in 0% to 3.8% versus 1.9%, with no severe hypoglycemia. LIMITATION: Open-label, short duration, only Chinese participants. CONCLUSION: Meaningful reductions in HbA1c levels were seen with bofanglutide in patients with T2DM; GIAEs were the most common and generally manageable. PRIMARY FUNDING SOURCE: Gan & Lee Pharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tianjin Medical University General Hospital, Tianjin, China (M.L.).
- The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China (Z.C.).
- Shandong Guoxin Yiyang Group Zaozhuang Central Hospital, Zaozhuang, China (L.L.).
- The Second Hospital of Jilin University, Changchun, China (H.C.).
- Chengdu Seventh People's Hospital, Chengdu, China (Jingyu Liu).
- Weifang Hospital of Traditional Chinese Medicine, Weifang, China (Jinling Liu).
Zitieren
APA
Liu, M., Cheng, Z., Lu, L., Cai, H., Liu, J., Liu, J., Zheng, Y., Wang, S., Zhao, J., Yang, W., Xie, T., Li, Y., He, A., Rodbard, H. W., & Chen, W. (2026). Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-04623
Vancouver
Liu M, Cheng Z, Lu L, Cai H, Liu J, Liu J, et al. Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes. Annals of Internal Medicine. 2026. doi:10.7326/annals-25-04623
BibTeX
@article{Liu2026,
author = {Liu, Ming and Cheng, Zhifeng and Lu, Li and Cai, Hanqing and Liu, Jingyu and Liu, Jinling and Zheng, Yueyue and Wang, Su and Zhao, Jing and Yang, Wei and Xie, Tian and Li, Yue and He, Anshun and Rodbard, Helena W and Chen, Wei},
title = {Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes},
journal = {Annals of Internal Medicine},
year = {2026},
doi = {10.7326/annals-25-04623}
}
EUVIMED